CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation: Involvement of the ubiquitin proteasome pathway

Tetsuzo Tauchi, Akihiko Yoshimura, Kazuma Ohyashiki

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective. BCR/ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph)-positive leukemia. A general understanding of BCR/ABL signaling events is emerging, but little is known about the endogenous inhibitors of p210 BCR/ABL. The present study focused attention on CIS1, a cytokine-inducible SH2 protein, as a potential physiologic antagonist for BCR/ABL. Materials and Methods. The murine hematopoietic cell line NSF/N1.H7 stably transfected with BCR/ABL was compared to the parental counterparts for induction of CIS1 by immunoblotting and immunoprecipitation. Cells were treated with a proteasome inhibitor to examine the effect of a proteasome inhibitor on CIS1 protein expression. To determine the effect of CIS1 on BCR/ABL-mediated transformation, we generated Rat-1 fibroblasts transfected with either a control vector, CIS1, BCR/ABL p210, or CIS1 plus BCR/ABL p210.ResultsThree forms of CIS1 with molecular masses of 32, 37, and 47 kDa were detected in BCR/ABL-transformed cells. The 47-kDa protein was a ubiquitinated protein. The proteasome inhibitor increased the formation of complexes between CIS1 and BCR/ABL. Transformation of p210 BCR/ABL was significantly suppressed in cells overexpressing CIS1. Conclusion. The results suggest that CIS1 is an endogenous inhibitor of p210 BCR/ABL and is likely to be important in the pathogenesis of Ph-positive leukemia.

Original languageEnglish
Pages (from-to)356-361
Number of pages6
JournalExperimental Hematology
Volume29
Issue number3
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Proteasome Inhibitors
Proteasome Endopeptidase Complex
Ubiquitin
Cytokines
Leukemia
Ubiquitinated Proteins
Philadelphia Chromosome
Proteins
Oncogene Proteins
Immunoprecipitation
Immunoblotting
Protein-Tyrosine Kinases
Fibroblasts
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation : Involvement of the ubiquitin proteasome pathway. / Tauchi, Tetsuzo; Yoshimura, Akihiko; Ohyashiki, Kazuma.

In: Experimental Hematology, Vol. 29, No. 3, 2001, p. 356-361.

Research output: Contribution to journalArticle

@article{835ab6bbea80433aab192b0b20301618,
title = "CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation: Involvement of the ubiquitin proteasome pathway",
abstract = "Objective. BCR/ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph)-positive leukemia. A general understanding of BCR/ABL signaling events is emerging, but little is known about the endogenous inhibitors of p210 BCR/ABL. The present study focused attention on CIS1, a cytokine-inducible SH2 protein, as a potential physiologic antagonist for BCR/ABL. Materials and Methods. The murine hematopoietic cell line NSF/N1.H7 stably transfected with BCR/ABL was compared to the parental counterparts for induction of CIS1 by immunoblotting and immunoprecipitation. Cells were treated with a proteasome inhibitor to examine the effect of a proteasome inhibitor on CIS1 protein expression. To determine the effect of CIS1 on BCR/ABL-mediated transformation, we generated Rat-1 fibroblasts transfected with either a control vector, CIS1, BCR/ABL p210, or CIS1 plus BCR/ABL p210.ResultsThree forms of CIS1 with molecular masses of 32, 37, and 47 kDa were detected in BCR/ABL-transformed cells. The 47-kDa protein was a ubiquitinated protein. The proteasome inhibitor increased the formation of complexes between CIS1 and BCR/ABL. Transformation of p210 BCR/ABL was significantly suppressed in cells overexpressing CIS1. Conclusion. The results suggest that CIS1 is an endogenous inhibitor of p210 BCR/ABL and is likely to be important in the pathogenesis of Ph-positive leukemia.",
author = "Tetsuzo Tauchi and Akihiko Yoshimura and Kazuma Ohyashiki",
year = "2001",
doi = "10.1016/S0301-472X(00)00673-1",
language = "English",
volume = "29",
pages = "356--361",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation

T2 - Involvement of the ubiquitin proteasome pathway

AU - Tauchi, Tetsuzo

AU - Yoshimura, Akihiko

AU - Ohyashiki, Kazuma

PY - 2001

Y1 - 2001

N2 - Objective. BCR/ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph)-positive leukemia. A general understanding of BCR/ABL signaling events is emerging, but little is known about the endogenous inhibitors of p210 BCR/ABL. The present study focused attention on CIS1, a cytokine-inducible SH2 protein, as a potential physiologic antagonist for BCR/ABL. Materials and Methods. The murine hematopoietic cell line NSF/N1.H7 stably transfected with BCR/ABL was compared to the parental counterparts for induction of CIS1 by immunoblotting and immunoprecipitation. Cells were treated with a proteasome inhibitor to examine the effect of a proteasome inhibitor on CIS1 protein expression. To determine the effect of CIS1 on BCR/ABL-mediated transformation, we generated Rat-1 fibroblasts transfected with either a control vector, CIS1, BCR/ABL p210, or CIS1 plus BCR/ABL p210.ResultsThree forms of CIS1 with molecular masses of 32, 37, and 47 kDa were detected in BCR/ABL-transformed cells. The 47-kDa protein was a ubiquitinated protein. The proteasome inhibitor increased the formation of complexes between CIS1 and BCR/ABL. Transformation of p210 BCR/ABL was significantly suppressed in cells overexpressing CIS1. Conclusion. The results suggest that CIS1 is an endogenous inhibitor of p210 BCR/ABL and is likely to be important in the pathogenesis of Ph-positive leukemia.

AB - Objective. BCR/ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Ph)-positive leukemia. A general understanding of BCR/ABL signaling events is emerging, but little is known about the endogenous inhibitors of p210 BCR/ABL. The present study focused attention on CIS1, a cytokine-inducible SH2 protein, as a potential physiologic antagonist for BCR/ABL. Materials and Methods. The murine hematopoietic cell line NSF/N1.H7 stably transfected with BCR/ABL was compared to the parental counterparts for induction of CIS1 by immunoblotting and immunoprecipitation. Cells were treated with a proteasome inhibitor to examine the effect of a proteasome inhibitor on CIS1 protein expression. To determine the effect of CIS1 on BCR/ABL-mediated transformation, we generated Rat-1 fibroblasts transfected with either a control vector, CIS1, BCR/ABL p210, or CIS1 plus BCR/ABL p210.ResultsThree forms of CIS1 with molecular masses of 32, 37, and 47 kDa were detected in BCR/ABL-transformed cells. The 47-kDa protein was a ubiquitinated protein. The proteasome inhibitor increased the formation of complexes between CIS1 and BCR/ABL. Transformation of p210 BCR/ABL was significantly suppressed in cells overexpressing CIS1. Conclusion. The results suggest that CIS1 is an endogenous inhibitor of p210 BCR/ABL and is likely to be important in the pathogenesis of Ph-positive leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0035108553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035108553&partnerID=8YFLogxK

U2 - 10.1016/S0301-472X(00)00673-1

DO - 10.1016/S0301-472X(00)00673-1

M3 - Article

C2 - 11274764

AN - SCOPUS:0035108553

VL - 29

SP - 356

EP - 361

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 3

ER -